These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20530250)

  • 1. Topic of histopathology blinding in nonclinical safety biomarker qualification studies.
    Burkhardt JE; Ennulat D; Pandher K; Solter PF; Troth SP; Boyce RW; Zabka TS
    Toxicol Pathol; 2010 Jun; 38(4):666-7. PubMed ID: 20530250
    [No Abstract]   [Full Text] [Related]  

  • 2. Recommendations for the evaluation of pathology data in nonclinical safety biomarker qualification studies.
    Burkhardt JE; Pandher K; Solter PF; Troth SP; Boyce RW; Zabka TS; Ennulat D
    Toxicol Pathol; 2011 Dec; 39(7):1129-37. PubMed ID: 22116771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualification of cardiac troponins for nonclinical use: a regulatory perspective.
    Hausner EA; Hicks KA; Leighton JK; Szarfman A; Thompson AM; Harlow P
    Regul Toxicol Pharmacol; 2013 Oct; 67(1):108-14. PubMed ID: 23876748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker qualification pilot process at the US Food and Drug Administration.
    Goodsaid F; Frueh F
    AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of potential gastrointestinal biomarkers in a PAK4 inhibitor-treated preclinical toxicity model to address unmonitorable gastrointestinal toxicity.
    John-Baptiste A; Huang W; Kindt E; Wu A; Vitsky A; Scott W; Gross C; Yang AH; Schaiff WT; Ramaiah SK
    Toxicol Pathol; 2012 Apr; 40(3):482-90. PubMed ID: 22395791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum chemical biomarkers of cardiac injury for nonclinical safety testing.
    Walker DB
    Toxicol Pathol; 2006; 34(1):94-104. PubMed ID: 16507550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospholipidosis in nonclinical toxicity studies.
    Berridge BR; Chatman LA; Odin M; Schultze AE; Losco PE; Meehan JT; Peters T; Vonderfecht SL;
    Toxicol Pathol; 2007 Feb; 35(2):325. PubMed ID: 17366328
    [No Abstract]   [Full Text] [Related]  

  • 9. Progress in capillary electrophoresis of biomarkers and metabolites between 2002 and 2005.
    Huck CW; Bakry R; Bonn GK
    Electrophoresis; 2006 Jan; 27(1):111-25. PubMed ID: 16315181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat.
    Harpur E; Ennulat D; Hoffman D; Betton G; Gautier JC; Riefke B; Bounous D; Schuster K; Beushausen S; Guffroy M; Shaw M; Lock E; Pettit S;
    Toxicol Sci; 2011 Aug; 122(2):235-52. PubMed ID: 21593213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research.
    Søreide K
    J Clin Pathol; 2009 Jan; 62(1):1-5. PubMed ID: 18818262
    [No Abstract]   [Full Text] [Related]  

  • 12. Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach.
    Pandher K; Leach MW; Burns-Naas LA
    Vet Pathol; 2012 Mar; 49(2):357-61. PubMed ID: 21810619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational medicine and the value of biomarker qualification.
    Goodsaid FM; Mendrick DL
    Sci Transl Med; 2010 Sep; 2(47):47ps44. PubMed ID: 20811041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Conference on Harmonisation; Guidance on E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Aug; 76(155):49773-4. PubMed ID: 21834216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimal ratio of cases to controls for estimating the classification accuracy of a biomarker.
    Janes H; Pepe M
    Biostatistics; 2006 Jul; 7(3):456-68. PubMed ID: 16428259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Environmental agent susceptibility assessment using existing and novel biomarkers as rapid noninvasive testing methods.
    Mandich A; Benfenati E; Cronin MT; Goksøyr A; Grøsvik BE; Kloas W; van Cauwenberge A; Viganò L
    Ann N Y Acad Sci; 2005 Apr; 1040():381-6. PubMed ID: 15891068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategic paths for biomarker qualification.
    Goodsaid FM; Frueh FW; Mattes W
    Toxicology; 2008 Mar; 245(3):219-23. PubMed ID: 18280028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nonclinical fertility study design for pharmaceuticals.
    Lerman SA; Hew KW; Stewart J; Stump DG; Wise LD
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):429-36. PubMed ID: 20025039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.